BR112020013419A8 - Composição compreendendo proteína receptora de gplb¿lfa recombinante - Google Patents

Composição compreendendo proteína receptora de gplb¿lfa recombinante

Info

Publication number
BR112020013419A8
BR112020013419A8 BR112020013419A BR112020013419A BR112020013419A8 BR 112020013419 A8 BR112020013419 A8 BR 112020013419A8 BR 112020013419 A BR112020013419 A BR 112020013419A BR 112020013419 A BR112020013419 A BR 112020013419A BR 112020013419 A8 BR112020013419 A8 BR 112020013419A8
Authority
BR
Brazil
Prior art keywords
recombinant
gplb
composition
receptor protein
recombinant polypeptides
Prior art date
Application number
BR112020013419A
Other languages
English (en)
Other versions
BR112020013419A2 (pt
Inventor
Booth Elizabeth
Montanini Virginia
A Hall John
berry Jody
Original Assignee
Grifols Diagnostic Solutions Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc, Hoffmann La Roche filed Critical Grifols Diagnostic Solutions Inc
Publication of BR112020013419A2 publication Critical patent/BR112020013419A2/pt
Publication of BR112020013419A8 publication Critical patent/BR112020013419A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Vários aspectos da invenção referem-se a polipeptídeos recombinantes que ligam especificamente Fator von Willebrand humano. Tais polipeptídeos recombinantes tipicamente incluem domínio extracelular modificado de Ibalfa de glicoproteína de plaqueta que tipicamente compreende pelo menos uma mutação selecionada de G233T, D235V, e K237V, e tais polipeptídeos recombinantes opcionalmente incluem um domínio de oligomerização.
BR112020013419A 2018-02-20 2019-02-15 Composição compreendendo proteína receptora de gplb¿lfa recombinante BR112020013419A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632870P 2018-02-20 2018-02-20
US62/632,870 2018-02-20
PCT/IB2019/051227 WO2019162813A1 (en) 2018-02-20 2019-02-15 COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN

Publications (2)

Publication Number Publication Date
BR112020013419A2 BR112020013419A2 (pt) 2020-12-01
BR112020013419A8 true BR112020013419A8 (pt) 2022-07-05

Family

ID=65685858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020013419A BR112020013419A8 (pt) 2018-02-20 2019-02-15 Composição compreendendo proteína receptora de gplb¿lfa recombinante

Country Status (12)

Country Link
US (1) US11746140B2 (pt)
EP (2) EP4386387A2 (pt)
JP (2) JP7373993B2 (pt)
KR (2) KR20210134990A (pt)
CN (1) CN110392693A (pt)
AR (1) AR114120A1 (pt)
AU (1) AU2019224735A1 (pt)
BR (1) BR112020013419A8 (pt)
CA (1) CA3086449A1 (pt)
TW (1) TW202000692A (pt)
UY (1) UY38092A (pt)
WO (1) WO2019162813A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074564B1 (en) * 1998-04-23 2008-12-10 Ajinomoto Co., Inc. Substance with antithrombotic activity and method for detecting glycokallidin
AR035779A1 (es) 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
JP2007537710A (ja) * 2003-06-11 2007-12-27 ワイス 血小板糖タンパク質ＩＢα改変体融合ポリペプチドおよびその使用法
US20050019224A1 (en) 2003-06-16 2005-01-27 Schering Corporation Virtual well plate system
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
US20070274999A1 (en) * 2006-05-18 2007-11-29 Shaw Gray D Method of treating disorders using platelet glycoprotein Ib alpha fusion polypeptides
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009026551A1 (en) 2007-08-23 2009-02-26 Bloodcenter Of Wisconsin, Inc. Methods and kits for measuring von willebrand factor
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
CN102279273A (zh) * 2011-07-19 2011-12-14 苏州大学 一种血管性血友病因子瑞斯托霉素辅因子酶联免疫试剂盒
EP2919013B1 (de) 2014-03-11 2016-11-02 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion
TW201910349A (zh) * 2017-08-10 2019-03-16 美商格里佛診斷方法股份有限公司 包含重組人類ｃｄ３８細胞外區域之組合物、方法及／或套組

Also Published As

Publication number Publication date
KR20190102214A (ko) 2019-09-03
US20220033473A1 (en) 2022-02-03
TW202000692A (zh) 2020-01-01
JP2020514269A (ja) 2020-05-21
US11746140B2 (en) 2023-09-05
EP3555123A1 (en) 2019-10-23
BR112020013419A2 (pt) 2020-12-01
JP7373993B2 (ja) 2023-11-06
CA3086449A1 (en) 2019-08-29
CN110392693A (zh) 2019-10-29
EP4386387A2 (en) 2024-06-19
EP3555123B1 (en) 2024-03-27
AR114120A1 (es) 2020-07-22
AU2019224735A1 (en) 2020-07-16
KR20210134990A (ko) 2021-11-11
JP2022110151A (ja) 2022-07-28
UY38092A (es) 2019-05-31
WO2019162813A1 (en) 2019-08-29
KR102391992B1 (ko) 2022-04-29

Similar Documents

Publication Publication Date Title
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
CO2017007665A2 (es) Proteínas de unión a icos
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
CY1124213T1 (el) Διαβιβαστες aav που περιεχουν γονιδιο κωδικοποιησης του παραγοντα viii
NZ756763A (en) Engineered transferrin receptor binding polypeptides
MX2020003190A (es) Degradadores de proteinas y usos de los mismos.
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
CO2020009827A2 (es) Polipéptidos de unión al receptor de transferrina y usos de estos.
BR112017006591A2 (pt) polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
PE20090359A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EA202092316A1 (ru) Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
MA40882B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
EA201792485A2 (ru) Комплекс фактора viii с xten и белком-фактором фон виллебранда и его применение (варианты)
BR112016015867A2 (pt) anticorpos de elevada afinidade e resistentes à agregação com base nas regiões variáveis vl e no derivado vhh
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202090649A1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
MY202395A (en) Gremlin-1 crystal structure and inhibitory antibody
BR112020013419A8 (pt) Composição compreendendo proteína receptora de gplb¿lfa recombinante
MD3497085T2 (ro) Sulfonamide în calitate de agoniști ai GPR40- și GPR120-
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
EA202092464A1 (ru) Способы получения стабильных композиций на основе белков

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: F. HOFFMANN-LA ROCHE AG (CH)